Surufatinib in G3 Neuroendocrine Tumors

Trial Title: Surufatinib in G3 Neuroendocrine Tumors

NCT ID: NCT05973968

Condition: Neuroendocrine Tumor Grade 3

Conditions: Official terms:
Neuroendocrine Tumors

Study type: Observational

Overall status: Not yet recruiting

Study design:

Time perspective: Prospective

Intervention:

Intervention type: Drug
Intervention name: Surufatinib
Description: Taking 28 days as a treatment cycle, the tumor was evaluated by imaging method every 8 weeks (±7 days) in the first 52 weeks, and then every 12 weeks (±7 days) until the disease progression (RECIST1.1) or death (during the treatment of the patient). The treatment and survival status of the tumor after disease progression were recorded.
Arm group label: surufatinib

Summary: The goal of this observational study is to learn about surufatinib in Refractory Metastatic G3 Neuroendocrine Tumors. The main questions it aims to answer are: - To evaluate the efficacy and safety of surufatinib in the treatment of second-line and posterior-line in G3 neuroendocrine tumors. - To explore the predictive value of blood perfusion parameters in curative effect. Participants will be given surufatinib 300mg QD, po, every 4 weeks as a course of treatment, continuous administration until PD, death or intolerable toxicity.

Detailed description: Currently, there is a lack of standard treatment for metastatic G3 neuroendocrine tumors, and CSCO guidelines recommend patients to enter clinical trials. The NCCN guidelines recommend that patients with G3 be divided into two groups according to Ki67 > 55%, SSTR expression, tumor load and progression, and are treated with chemotherapy, somatostatin, mTOR inhibitor, and Sunitinib (limited to pancreatic neuroendocrine tumors). Among them, a small sample study showed that there was no significant difference in the efficacy of sunitinib in the treatment of pancreatic neuroendocrine tumors (PFS) between G3 and G1/2. surufatinib capsule is a new oral tyrosine kinase inhibitor. Approved by NMPA for unresectable locally advanced or metastatic, advanced non-functional, well differentiated (G1, G2) non-pancreatic (December 2020) and pancreatic (June 2021) neuroendocrine tumors, in the 2022 Chinese guidelines for integrated diagnosis and treatment of tumors, it is recommended to choose surufatinib after the second line of treatment for G3 NEN patients with Ki67 < 55%. However, there is still a lack of data on the efficacy and safety of surufatinib in the real world in China, and its efficiency in G3 NEN is worth exploring. The goal of this observational study is to learn about surufatinib in Refractory Metastatic G3 Neuroendocrine Tumors. The main questions it aims to answer are: - To evaluate the efficacy and safety of surufatinib in the treatment of second-line and posterior-line in G3 neuroendocrine tumors. - To explore the predictive value of blood perfusion parameters in curative effect. Participants will be given surufatinib 300mg QD, po, every 4 weeks as a course of treatment, continuous administration until PD, death or intolerable toxicity. Taking 28 days as a treatment cycle, the tumor was evaluated by imaging method every 8 weeks (±7 days) in the first 52 weeks, and then every 12 weeks (±7 days) until the disease progression (RECIST1.1) or death (during the treatment of the patient). The treatment and survival status of the tumor after disease progression were recorded. Safety indicators include: adverse events, laboratory tests, vital signs and changes in ECG and echocardiography.

Criteria for eligibility:

Study pop:
Patients with G3 neuroendocrine tumor

Sampling method: Probability Sample
Criteria:
Inclusion Criteria: 1. Have fully understood this study and voluntarily signed the informed consent form; 2. Age ≥ 18 years old, both male and female; 3. Neuroendocrine tumors diagnosed by histopathology or cytology (patients with neuroendocrine tumors diagnosed as G3 according to WHO2019 criteria, and Ki67 index ≤ 55%); 4. Progress after at least one systemic chemotherapy; 5. According to the evaluation criteria of solid tumor efficacy (RECISTV1.1), there is at least one measurable lesion. 6. Palliative radiotherapy at the localized site was allowed for more than 7 days since the end of the last systematic treatment, which has been over 4 weeks. 7. Expected survival ≥ 12 weeks; 8. The researchers assessed that they could benefit; 9. Have enough organ and bone marrow function; 10. Fertile male or female patients voluntarily used effective contraceptive methods during the study period and within 6 months of the last study, such as double barrier contraceptives, condoms, oral or injection contraceptives, intrauterine devices, etc. All female patients will be considered fertile unless the female patient has undergone natural menopause, artificial menopause or sterilization (such as hysterectomy, bilateral adnexectomy or radioactive ovarian irradiation). Otherwise, the serum of female patients showed that they were not pregnant within 7 days before the study and must be non-lactation patients. Exclusion Criteria: 1. Other malignant tumors have been diagnosed in the past 5 years, except for skin basal cell carcinoma, skin squamous cell carcinoma, cervical cancer in situ and breast cancer after effective treatment. 2. At the same time, receive other experimental drugs or approved or under research anti-tumor therapy; 3. Patients with contraindications of Surufatinib (such as active bleeding, ulcer, intestinal perforation, intestinal obstruction, uncontrollable hypertension, III-IV cardiac insufficiency, severe hepatic and renal insufficiency within 30 days after major operation, etc.). 4. The patient currently has any disease or condition that affects drug absorption, or the patient cannot take Surufatinib orally; 5. It has been proved to be allergic to experimental drugs and any components in their excipients; 6. Women who are pregnant (positive for pre-medication pregnancy test) or breastfeeding; 7. Patients with large pleural effusion or ascites need drainage; 8. Any other disease, with clinically significant metabolic abnormalities, physical examination abnormalities or laboratory abnormalities, according to the researchers, there is reason to suspect that the patient has a disease or state that is not suitable for the use of research drugs (such as having seizures and requiring treatment), or will affect the interpretation of the findings or put the patient at high risk; 9. Drugs containing Hypericum perforatum were taken within 3 weeks before treatment, or other strong inducers or inhibitors of CYP3A4 were taken in the previous 2 weeks. 10. According to the researchers, the subjects have other factors that may lead to the termination of this study or are not suitable for inclusion, such as other serious concomitant diseases (such as severe diabetes, thyroid disease, spinal cord compression, superior vena cava syndrome, mental illness), severe laboratory abnormalities, family or social factors, which will affect the safety of the subjects, or the collection of data and samples.

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Start date: August 2023

Completion date: June 2025

Lead sponsor:
Agency: Qilu Hospital of Shandong University
Agency class: Other

Collaborator:
Agency: Shandong Provincial Hospital
Agency class: Other

Collaborator:
Agency: The Affiliated Hospital of Qingdao University
Agency class: Other

Collaborator:
Agency: Yantai Yuhuangding Hospital
Agency class: Other

Collaborator:
Agency: Weifang People's Hospital
Agency class: Other

Source: Qilu Hospital of Shandong University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05973968